GRIN2B
Glutamate receptor ionotropic, NMDA 2B
As of the edition of 20 October 2026, GRIN2B (glutamate receptor ionotropic, NMDA 2B, UniProt Q13224) has 21 drugs tested at it and 29 companies on the list, 8 on route A and 7 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q13224
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 36
- Disease areas
- Mental health; Nervous system; Cancer; Chemically induced; Injuries; Lungs and airways; Inherited and neonatal; Infections
- Registered trials of its drugs
- 1,373
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 6 |
| Active | 2 |
| Went quiet | 6 |
| Stopped | 6 |
| Status not established | 1 |
| Total | 21 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Ketamine | Marketed | Phase 4 | none listed |
| Esketamine | Marketed | Phase 4 | Ends 2028 |
| Memantine | Marketed | Phase 4 | none listed |
| Amantadine | Marketed | Phase 4 | none listed |
| Acamprosate | Marketed | Phase 4 | none listed |
| Rapastinel | Stopped | Phase 3 | none listed |
| Neramexane | Stopped | Phase 3 | none listed |
| Lanicemine | Went quiet | Phase 2 | none listed |
| AV-101 | Stopped | Phase 3 | none listed |
| Radiprodil | Active | Phase 3 | none listed |
| Apimostinel | Active | Phase 2 | none listed |
| Rislenemdaz | Went quiet | Phase 2 | none listed |
12 of 21 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 8 |
| Route B | 7 |
| Engaged | 6 |
| Undetermined | 8 |
| Total on the list | 29 |
| Company | Route |
|---|---|
| Pfizer | Route B |
| AstraZeneca | Route A |
| Viatris | Route B |
The other 26 companies at GRIN2B
In the product29 companies in all; 26 are not named here, and no score is.
See the 29 companies at GRIN2B, ranked, with the facts behind eachRequest access. Nothing is shown until you do.